Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT04801797
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT04659616
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 1
- Registration Number
- NCT04562792
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- wang, jianxiang
- Target Recruit Count
- 50
- Registration Number
- NCT04440267
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
AflacLL1901 (CHOA-AML)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT04326439
- Locations
- 🇺🇸
Egleston Hospital, Atlanta, Georgia, United States
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 172
- Registration Number
- NCT04174612
- Locations
- 🇮🇹
Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia, Orbassano, Italy
🇮🇹Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia, Mestre, Italy
🇮🇹Aou Policlinico P. Giaccone - Palermo - Uo Ematologia, Palermo, Italy
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT04061239
- Locations
- 🇦🇹
Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
🇩🇪Universitätsklinikum Augsburg, Augsburg, Germany
🇩🇪Klinikum Frankfurt (Oder) GmbH, Frankfurt, Germany
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- 🇳🇱
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
🇫🇷Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France
🇧🇪UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
- Conditions
- Interventions
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 36
- Registration Number
- NCT03962465
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.